BioStock: Evaxion receives Fast Track for cancer vaccine candidate

2023 is off to a good start for Evaxion Biotech. After receiving the go-ahead from the FDA to initiate a phase IIb trial their personalised cancer therapy EVX-01, which builds on the company’s proprietary AI platform, PIONEER. The Danish company has announced receiving fast track designation for the drug candidate in combination with Keytruda – a form of validation of its AI-driven immunotherapy development platform.

Read the article at biostock.se:

Evaxion receives Fast Track for cancer vaccine candidate - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/